Clinical Trial Update: Long-Term Follow-up of Subjects Who Were Treated With ST-920

View source ↗

Summary

This update provides long-term follow-up information for subjects treated with ST-920 in Fabry disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fabry Disease

Drugs mentioned

• ST-920

Snippet

Sponsor: Sangamo Therapeutics | Conditions: Fabry Disease, Fabry Disease, Cardiac Variant | Status: ENROLLING_BY_INVITATION